129 related articles for article (PubMed ID: 37743629)
1. Comment on "Effect of imatinib treatment on renal anemia in chronic myeloid leukemia patients".
Ansari R; Taghizadeh-Ghehi M
J Oncol Pharm Pract; 2023 Dec; 29(8):2057-2058. PubMed ID: 37743629
[No Abstract] [Full Text] [Related]
2. Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib.
Cesini L; Carmosino I; Breccia M; De Benedittis D; Mohamed S; De Luca ML; Colafigli G; Molica M; Scalzulli E; Massaro F; Mariggiò E; Rizzo L; Loglisci MG; Scamuffa MC; Vozella F; Diverio D; Mancini M; Alimena G; Foà R; Latagliata R
Oncol Res Treat; 2019; 42(12):660-664. PubMed ID: 31593970
[TBL] [Abstract][Full Text] [Related]
3. Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients.
Singh AK; Vidyadhari A; Bhurani D; Agrawal N; Ahmed R; Sharma M
J Oncol Pharm Pract; 2023 Dec; 29(8):1928-1934. PubMed ID: 36862651
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate-induced pseudoporphyria in a patient with chronic myeloid leukemia.
Batrani M; Salhotra M; Kubba A; Agrawal M
Indian J Dermatol Venereol Leprol; 2016; 82(6):727-729. PubMed ID: 27716725
[No Abstract] [Full Text] [Related]
5. Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.
Giuntoli S; Tanturli M; Di Gesualdo F; Barbetti V; Rovida E; Dello Sbarba P
Haematologica; 2011 Feb; 96(2):204-12. PubMed ID: 21071498
[TBL] [Abstract][Full Text] [Related]
6. Continuing Imatinib Treatment for Chronic Myeloid Leukemia Patients Who Had Serious Adverse Events at the Onset of Therapy.
Li Y; Wang CL; Din B; Yu L; Zhu J
Acta Haematol; 2017; 137(3):158-162. PubMed ID: 28399540
[No Abstract] [Full Text] [Related]
7. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
8. Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia.
Sakurai M; Kikuchi T; Karigane D; Kasahara H; Matsuki E; Hashida R; Yamane Y; Abe R; Koda Y; Toyama T; Kato J; Shimizu T; Yokoyama Y; Suzuki S; Nakamura T; Okamoto S; Mori T
Int J Hematol; 2019 Mar; 109(3):292-298. PubMed ID: 30680668
[TBL] [Abstract][Full Text] [Related]
9. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
10. Imatinib-induced pyoderma gangrenosum in a patient with chronic myeloid leukemia.
Faraci AG; Genovese G; Ferrucci S; Marzano AV
Indian J Dermatol Venereol Leprol; 2021; 87(5):704-706. PubMed ID: 34114414
[No Abstract] [Full Text] [Related]
11. Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.
Singh S; Sharma PK
Indian J Pharmacol; 2016; 48(4):458-459. PubMed ID: 27756963
[TBL] [Abstract][Full Text] [Related]
12. Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.
Elias MH; Azlan H; Sulong S; Baba AA; Ankathil R
Cancer Rep (Hoboken); 2018 Aug; 1(2):e1111. PubMed ID: 32721103
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse reaction to imatinib in a case of childhood chronic myeloid leukemia.
Saroha M
Pediatr Blood Cancer; 2020 Dec; 67(12):e28490. PubMed ID: 32573963
[No Abstract] [Full Text] [Related]
14. Imatinib-Associated Pneumocystis jirovecii Pneumonia in a Patient With Chronic Myeloid Leukemia.
Daw J; Thapa B; Chahine J; Lak H; Perez O; Nair R; Alomari M; Haddad A
Am J Ther; 2020; 27(4):e406-e409. PubMed ID: 31356343
[No Abstract] [Full Text] [Related]
15. Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia-Reply.
Douxfils J; Haguet H; Dogné JM
JAMA Oncol; 2016 Jun; 2(6):829. PubMed ID: 27281625
[No Abstract] [Full Text] [Related]
16. Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients.
Chandrasekhar C; Kumar PS; Sarma PVGK
Sci Rep; 2019 Feb; 9(1):2412. PubMed ID: 30787317
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate induced erythroderma: A rare case series.
Kumar S; Mahajan BB; Kaur S; Banipal RP; Singh A
J Cancer Res Ther; 2015; 11(4):993-6. PubMed ID: 26881566
[TBL] [Abstract][Full Text] [Related]
18. Second primary malignancies in chronic myeloid leukemia patients.
Caliskan T; Eskazan AE
J Cancer Res Ther; 2015; 11(4):1042. PubMed ID: 26881669
[No Abstract] [Full Text] [Related]
19. Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!
Eşkazan AE
Cancer; 2023 Feb; 129(4):643-644. PubMed ID: 36477711
[No Abstract] [Full Text] [Related]
20. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Sawyers CL
Semin Hematol; 2001 Jul; 38(3 Suppl 8):15-21. PubMed ID: 11526597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
